Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Institutional investor

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Nov 17, 2023 2:09pm

137 Views

Post# 35741595

RE:RE:RE:RE:RE:RE:RE:Institutional investor

Leede Jones Gables assumes a responsibility to act fairly, honestly and in good faith with our clients, which also means Anson Funds Management as a client on the other side of the deal. That left ONCY to do its own DD.

https://leedejonesgable.com/wp-content/uploads/Relationship-Disclosure-July-2021.pdf

<< Previous

Bullboard Posts

Next >>

Changing Europe’s dependency on HREE from China